(VTR) Ventas - Overview
Stock: Senior Housing, Medical Offices, Research Centers
| Risk 5d forecast | |
|---|---|
| Volatility | 19.1% |
| Relative Tail Risk | -5.60% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.29 |
| Alpha | 25.66 |
| Character TTM | |
|---|---|
| Beta | 0.226 |
| Beta Downside | 0.354 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.35% |
| CAGR/Max DD | 1.26 |
EPS (Earnings per Share)
Revenue
Primary Risks
P/E ratio: 161.7736
Description: VTR Ventas February 11, 2026
Ventas, Inc. (NYSE: VTR) is a S&P 500 REIT that owns and operates roughly 1,400 senior-housing, outpatient-medical, research-center and healthcare-facility properties across North America and the United Kingdom, positioning it as a core player in the “longevity economy.” Its business model relies on a mix of stable, long-term leases and on-site service revenues, which it claims are enhanced by the Ventas OI data-analytics platform and a financially disciplined balance sheet.
Key recent metrics (FY 2025, disclosed in the March 2026 10-K):
• Occupancy in senior-housing assets remained high at 96.2 % (±0.3 % YoY), supporting steady rental income.
• Funds from Operations (FFO) grew 6.1 % year-over-year to $1.34 billion, translating to an adjusted FFO-per-share of $5.28.
• The dividend yield hovered around 5.5 % (annualized) with a payout ratio of 84 % of reported FFO.
• Net debt to EBITDA stood at 6.2 ×, reflecting a modest increase from 5.9 × a year earlier due to recent acquisitions.
Macro- and sector-level drivers that materially affect Ventas’ outlook include:
• Demographic tailwinds: the U.S. population aged 65+ is projected to rise from 56 million in 2024 to 71 million by 2034, expanding the addressable market for senior-housing and outpatient services.
• Medicare and Medicaid reimbursement trends: recent CMS policy adjustments have modestly increased per-capita spending on post-acute care, but ongoing regulatory uncertainty could compress margins if reimbursement growth stalls.
• Interest-rate environment: the Fed’s policy rate of 5.25-5.50 % in early 2026 raises refinancing costs for REITs, making the company’s strong cash flow and low-coupon debt issuance strategy a critical risk mitigant.
For a deeper quantitative comparison of Ventas’ valuation metrics against peers, the ValueRay platform offers a concise, data-driven dashboard.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 251.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.69 > 1.0 |
| NWC/Revenue: -1.06% < 20% (prev 0.95%; Δ -2.01% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.68b > Net Income 251.4m |
| Net Debt (12.48b) to EBITDA (2.24b): 5.57 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (480.8m) vs 12m ago 12.43% < -2% |
| Gross Margin: -5.90% > 18% (prev 0.43%; Δ -632.6% > 0.5%) |
| Asset Turnover: 21.70% > 50% (prev 18.80%; Δ 2.89% > 0%) |
| Interest Coverage Ratio: 1.14 > 6 (EBITDA TTM 2.24b / Interest Expense TTM 753.8m) |
Altman Z'' -1.74
| A: -0.00 (Total Current Assets 1.33b - Total Current Liabilities 1.39b) / Total Assets 27.59b |
| B: -0.27 (Retained Earnings -7.53b / Total Assets 27.59b) |
| C: 0.03 (EBIT TTM 859.6m / Avg Total Assets 26.89b) |
| D: -1.00 (Book Value of Equity -14.98b / Total Liabilities 15.01b) |
| Altman-Z'' Score: -1.74 = D |
Beneish M -3.54
| DSRI: 0.93 (Receivables 415.6m/375.7m, Revenue 5.83b/4.92b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.08 (AQ_t 0.08 / AQ_t-1 0.93) |
| SGI: 1.18 (Revenue 5.83b / 4.92b) |
| TATA: -0.05 (NI 251.4m - CFO 1.68b) / TA 27.59b) |
| Beneish M-Score: -3.54 (Cap -4..+1) = AAA |
What is the price of VTR shares?
Over the past week, the price has changed by +0.82%, over one month by +9.93%, over three months by +8.38% and over the past year by +32.17%.
Is VTR a buy, sell or hold?
- StrongBuy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89.2 | 3.8% |
| Analysts Target Price | 89.2 | 3.8% |
VTR Fundamental Data Overview February 20, 2026
P/E Forward = 149.2537
P/S = 7.0002
P/B = 3.2944
P/EG = 1.7374
Revenue TTM = 5.83b USD
EBIT TTM = 859.6m USD
EBITDA TTM = 2.24b USD
Long Term Debt = 13.01b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, two quarters ago)
Debt = 13.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.48b USD (from netDebt column, last quarter)
Enterprise Value = 53.20b USD (40.72b + Debt 13.22b - CCE 741.1m)
Interest Coverage Ratio = 1.14 (Ebit TTM 859.6m / Interest Expense TTM 753.8m)
EV/FCF = 40.41x (Enterprise Value 53.20b / FCF TTM 1.32b)
FCF Yield = 2.47% (FCF TTM 1.32b / Enterprise Value 53.20b)
FCF Margin = 22.57% (FCF TTM 1.32b / Revenue TTM 5.83b)
Net Margin = 4.31% (Net Income TTM 251.4m / Revenue TTM 5.83b)
Gross Margin = -5.90% ((Revenue TTM 5.83b - Cost of Revenue TTM 6.18b) / Revenue TTM)
Gross Margin QoQ = -136.0% (prev 41.58%)
Tobins Q-Ratio = 1.93 (Enterprise Value 53.20b / Total Assets 27.59b)
Interest Expense / Debt = 1.17% (Interest Expense 154.5m / Debt 13.22b)
Taxrate = 21.0% (US default 21%)
NOPAT = 679.1m (EBIT 859.6m * (1 - 21.00%))
Current Ratio = 0.96 (Total Current Assets 1.33b / Total Current Liabilities 1.39b)
Debt / Equity = 1.06 (Debt 13.22b / totalStockholderEquity, last quarter 12.53b)
Debt / EBITDA = 5.57 (Net Debt 12.48b / EBITDA 2.24b)
Debt / FCF = 9.48 (Net Debt 12.48b / FCF TTM 1.32b)
Total Stockholder Equity = 11.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.93% (Net Income 251.4m / Total Assets 27.59b)
RoE = 2.10% (Net Income TTM 251.4m / Total Stockholder Equity 11.97b)
RoCE = 3.44% (EBIT 859.6m / Capital Employed (Equity 11.97b + L.T.Debt 13.01b))
RoIC = 2.74% (NOPAT 679.1m / Invested Capital 24.81b)
WACC = 5.32% (E(40.72b)/V(53.94b) * Re(6.75%) + D(13.22b)/V(53.94b) * Rd(1.17%) * (1-Tc(0.21)))
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 8.69%
[DCF Debug] Terminal Value 88.33% ; FCFF base≈1.11b ; Y1≈1.36b ; Y5≈2.25b
Fair Price DCF = 111.9 (EV 65.62b - Net Debt 12.48b = Equity 53.14b / Shares 475.0m; r=5.90% [WACC]; 5y FCF grow 23.49% → 2.90% )
EPS Correlation: 44.09 | EPS CAGR: 6.54% | SUE: 0.20 | # QB: 0
Revenue Correlation: 98.00 | Revenue CAGR: 12.18% | SUE: 2.54 | # QB: 6
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=N/A | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=0.66 | Chg30d=+0.092 | Revisions Net=+1 | Growth EPS=+45.5% | Growth Revenue=+15.2%
EPS next Year (2027-12-31): EPS=0.97 | Chg30d=+0.007 | Revisions Net=-1 | Growth EPS=+47.2% | Growth Revenue=+12.3%